Zydus revenue rises 29%, but costs drive an 8.97-point margin squeeze
Operating profit fell 6.02% year on year as expenses grew faster than revenue, while the stock's initial decline exceeded its usual post-results move.
Filed 04 Nov 2026, 12:19 IST · Zydus Lifesciences Ltd (ZYDUSLIFE)
Key takeaways
- Revenue grew 29.17% year on year, but operating profit fell 6.02% as expenses rose 46.45%.
- Operating margin narrowed 8.97 percentage points year on year to 23.95%, its second consecutive quarterly decline from the Q4FY26 peak of 33.67%.
- The stock fell 4.23% initially, a larger move than its 2.8% median absolute reaction after the past eight results.
Price around the results
Revenue growth did not convert into operating profit
Zydus Lifesciences' consolidated revenue grew 29.17% year on year, but expenses increased 46.45%, causing operating profit to decline 6.02%. Profit before tax fell 25.46% as interest expense rose 84.6% and depreciation doubled year on year. Net profit consequently declined 25.1%, with EPS down 25.82%.
Margins slipped again as costs outpaced sales
Operating margin narrowed 8.97 percentage points year on year because costs grew faster than revenue, and slipped another 0.12 percentage points sequentially as revenue fell 1.34% while expenses declined only 1.19%. The 23.95% margin is below the 24.07% recorded in Q1FY27 and follows the fall from 33.67% in Q4FY26, marking two consecutive quarterly declines. Other income contributed 12.58% of pre-tax profit, while the 0.35-percentage-point year-on-year tax-rate reduction provided only a limited offset.
India branded formulations and new products were focus areas
Management said India branded formulations grew 19% year on year in Q2FY27 and that its Indian Consumer Wellness brands retained dominant market share. The company said it launched five products in North America and continued investing in a resilient product portfolio. Management also reported organic capex of Rs 4,655 million and said its emerging-markets strategy was focused on therapy-led, market-specific offerings.
Initial share reaction was unusually weak for Zydus
The stock fell 4.23% initially and underperformed by 4.86%, with trading volume at 3.58 times the reference level. That reaction was weaker than the stock's usual post-results pattern: seven of the past eight reactions were positive, and the median absolute move was 2.8%. The 23.95% operating margin remained 2.55 percentage points above the 21.4% median for the 69 Healthcare peers that had reported the same quarter.
Q2FY27 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q2FY27 | Q1FY27 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹7,910 cr | ₹8,017 cr | -1.34% | +29.17% |
| Other income | ₹159 cr | ₹126 cr | +26.25% | +98.37% |
| Expenses | ₹6,015 cr | ₹6,088 cr | -1.19% | +46.45% |
| Operating profit | ₹1,895 cr | ₹1,929 cr | -1.81% | -6.02% |
| Operating margin (%) | 23.95% | 24.07% | — | — |
| Interest | ₹187 cr | ₹156 cr | +19.87% | +84.60% |
| Depreciation | ₹605 cr | ₹555 cr | +8.98% | +100.23% |
| Profit before tax | ₹1,262 cr | ₹1,344 cr | -6.15% | -25.46% |
| Tax | ₹334 cr | ₹354 cr | -5.70% | -26.43% |
| Net profit | ₹928 cr | ₹990 cr | -6.31% | -25.10% |
| EPS (₹) | ₹9.28 | ₹9.35 | -0.75% | -25.82% |
Operating margin of 23.95% compares with a Healthcare sector median of 21.40% across 69 peers that have reported Q2FY27.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | -4.23% | -4.86% |
Volume on the results session was 3.58× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- India branded formulations grew 19% year over year during Q2 FY27.
Expansion
- Organic capex was Rs. 4,655 million during Q2 FY27.
New products
- The North America business launched five new products during Q2 FY27.
New initiatives
- In emerging markets, the company adopted a focused, therapy-led approach and tailored offerings to specific markets.
- The company is continuing to invest in building a resilient product portfolio.
Competition
- Consumer Wellness brands in India continued to hold dominant market share.
What to watch
- Whether operating margin holds above 23.95% after two consecutive quarterly declines.
- Whether interest expense moderates after rising 84.6% year on year.
- Whether India branded formulations sustain growth after the 19% year-on-year increase.